Bristol Myers Squibb (BMY)
(Delayed Data from NYSE)
$44.23 USD
+0.92 (2.12%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $44.29 +0.06 (0.14%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth D Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BMY 44.23 +0.92(2.12%)
Will BMY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BMY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BMY
Economy Heating Up on PCE for June
Bristol Myers Beats on Q2 Earnings and Sales, Raises '25 Sales View
BMY: What are Zacks experts saying now?
Zacks Private Portfolio Services
PCE Comes in Warmer Than Expected
Bristol Myers (BMY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Bristol Myers Squibb (BMY) Q2 Earnings and Revenues Top Estimates
Other News for BMY
Earnings Scorecard: 18 out of 21 healthcare firms beat earnings forecast this week
Notable healthcare headlines for the week: Trump’s ultimatum to big pharma, Novo Nordisk, UnitedHealth and Moderna in focus
Bristol Myers (BMY) Price Target Reduced by Bernstein After Q2 Report
Bristol Myers price target lowered by $4 at Bernstein, here's why
Bristol-Myers Squibb: Declines Have Gone Too Far